EUCTR2020-000954-86-HU进行中（未招募）1 期
A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients with Recurrent or metastatic HER2 negative Breast Cancer
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 476
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Subjects who are = 19 years of age on the date of written informed consent.
- •2) Subjects with confirmation of primary, recurrent or metastatic HER2 negative breast cancer based on histopathology examination (tumor characteristics should be confirmed by histological or cytological evaluation). However, in case of a metastasis or recurrence, it is not required to be verified again by histopathology, i.e it is possible to register with imaging alone.
- •(1) Subjects are eligible for the study regardless of hormone receptor status (ER/PR positive or negative).
- •(2) ER/PR(+) is defined as cells expressing hormone receptors >1% in immunohistochemistry (IHC) analysis of collected samples.
- •3) HER2-negative from tumor sample (primary or metastatic) is confirmed with one of the followings as NCCN guiline 20197 (HER2 test should be performed using samples of metastatic site, if metastasis is confirmed and samples can be collected from the metastatic lesions.)
- •(1) HER2 negative by validated immunohistochemistry (IHC) assay:
- •- IHC 0, 1+
- •- When IHC 2+, must reflex test with ISH (if same specimen), or order new test with IHC or dual probe in situ hybridization (ISH) (if new specimen available)
- •(2) HER2 negative by validated dual-probe ISH assay:
- •- HER2/CEP17 ratio < 2.0 and average HER2 copy number < 4.0 signals/cell
- •(3) HER2 negative by concurrent IHC and ISH results:
- •- HER2/CEP17 ratio = 2.0 and average HER2 copy number < 4.0 signals/cell and concurrent IHC 0-1+ or 2+
- •- HER2/CEP17 ratio < 2.0 and average HER2 copy number = 6.0 signals/cell and concurrent IHC 0-1+
- •- HER2/CEP17 ratio < 2.0 and average HER2 copy number = 4.0 and <6.0 signals/cell and concurrent IHC 0-1+ or 2+
- •4) Subjects with life expectancy = 12 weeks
- •5) Subjects with Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- •6) Subjects with measurable or evaluable lesions identified by RECIST version 1.1. (However, for phase II study, only subjects with measurable lesions can be enrolled.)
- •7) Subjects with confirmed adequate hematologic, renal and liver function as follows:
- •(1) Absolute neutrophil count (ANC) = 1,500/µL
- •(2) Platelet = 100,000/µL
- •(3) Hemoglobin = 9.0 g/dL
- •(4) Serum creatinine = 1.5 X ULN (but, subjects with CrCl or eGFR = 60 mL/min may participate)
- •(5) Serum calcium level = 12 mg/dL
- •(6) Total bilirubin = 1.5 X ULN (except for elevated total bilirubin due to Gilbert’s Syndrome)
- •(7) Liver function tests:
- •- If there is no evidence of liver metastases: ALT and AST = 2.5 x ULN
- •- If liver metastases are documented: ALT and AST = 5 x ULN
- •8) If subjects with central nervous system metastasis who should be stable for more than 4 weeks prior to randomization
- •(1) If subjects have a history of steroid administration, such patient can participate if he/she have discontinued steroid, or reduce or maintain dexamethasone administration of up to 4mg per day (or equivalent dosage) for more than 4 weeks prior to randomization date.
- •(2) Brain-imaging should be used to confirm that there are no new lesions and if subjects have symptoms of CNS metastasis, the investigator should use brain-imaging to confirm such case, at the investigator’s discretion.
- •9) Subjects who understand and are willing to comply with the protocol at the judgment of the investigator
- •10) Subjects who voluntarily agree to participate in the study and sign the informed consent form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subj
排除标准
- •1) Subjects expected to have hypersensitivity to active ingredient and any component of this investigational product.
- •2) Subjects who previously received drugs of taxane class (subjects who administer the last dose of drug of taxane class = 1 year ago as from the randomization day and have recurrence confirmed can be enrolled)
- •3) Subjects receiving chemotherapy for recurrent or metastatic HER2 negative breast cancer before screening for the study. However, the following subjects should be allowed to participate:
- •(1) Subjects who had the last administration of adjuvant or neoadjuvant chemotherapy from randomization for prior breast cancer that is not recurrent or metastatic, and its toxic symptoms have disappeared.
- •(2) ER/PR(+) subjects can be enrolled regardless of lines of endocrine therapy. (Alone or with CDK4/6 inhibitors, or mTOR inhibitors.)
- •4) Subjects who received radiotherapy within 2 weeks from the randomization day (subjects who have completed local radiotherapy as palliative therapy for the purpose of pain relief for sites (eg, sites of bone metastasis, etc.) other than the target lesion and have recovered from the resulting acute toxicity (eg, bone marrow suppression) can participate.)
- •5) Subjects with confirmed heart failure of New York Heart Association (NYHA) class 2 or higher, or clinically significant arrhythmia uncontrolled by drug treatments, at the time of study entry.
- •6) Subjects with confirmed cardiovascular disease (including unstable angina pectoris, myocardial infarction, stroke, and transient ischemic attack) that occurred within 24 weeks prior to study entry, which is deemed to be clinically significant by the investigator
- •7) Subjects whose left ventricular ejection fraction (LVEF) measured by echocardiogram, MUGA scan, or standard procedures of study site is < lower limit of normal (50%, if the institutional lower limit of normal is not set) within 12 weeks prior to study entry
- •8) Subjects with uncontrolled hypertension at the time of randomization (SBP > 140 mmHg or DBP > 90 mmHg despite drug treatments)
- •9) Subjects who have a history of active hepatitis B or C, or hepatobiliary disorders confirmed by medical records or medical examination
- •[However, the following subjects may participate:
- •(1) Subjects with Gilbert’s Syndrome, asymptomatic gallstone, liver metastases, or stable chronic liver disease may participate at the discretion of the investigator.
- •(2) Healthy carriers of hepatitis B who agree on prophylactic antiviral agent during chemotherapy or C virus can participate if HBV-DNA or HCV RNA titer is negative]
- •10) Those who have been confirmed to be positive for human immunodeficiency virus (HIV) through medical records or medical examination
- •11) Confirmed neuropathy grade = 2 (based on CTCAE v4.03) at the time of study entry
- •12) Subjects with confirmed uncontrolled intercurrent disease or condition including significant mental disease or social status which, in the investigator's judgment, may affect compliance with study procedures
- •13) Subjects with a history of primary malignancy other than breast cancer. However, the subjects should be allowed to participate if:
- •(1) It has been at least 5 years and they are disease-free since completion of tumor treatment
- •14) Subjects who are expected to newly start prophylactic use of bisphosphonate or RANKL inhibitor for bone metastasis during clinical study, at the discretion of investigator. (However, subjects on the drug for bone metastasis or osteoporosi
研究者
相似试验
进行中（未招募）
1 期
A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients with Recurrent or metastatic HER2 negative Breast CancerRecurrent or metastatic HER2 negative Breast CancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000954-86-BGDaehwa Pharmaceutical Co., Ltd.556
进行中（未招募）
1 期
An open-label, multicenter, multinational Phase IIIfollow-up study to investigate the long-term safetyand efficacy of Sarizotan HCl 1 mg b.i.d. inpatients with Parkinson's disease suffering fromtreatment-associated dyskinesia (PADDY-O) - PADDY-OTreatment- Associated Dyskinesia in Parkinson´s DiseaseEUCTR2005-000444-84-ESMerck KGaA
进行中（未招募）
不适用
An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson s disease suffering from treatment-associated dyskinesia PADDY-O .EUCTR2005-000444-84-ITMERCK S.P.A.800
进行中（未招募）
不适用
An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY-OEUCTR2005-000444-84-FIMerck KGaA800
进行中（未招募）
1 期
An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia - PADDY-OTreatment-Associated Dyskinesia in Parkinson's DiseaseEUCTR2005-000444-84-GBMerck KGaA